ACTRN12621000904875
Recruiting
N/A
Gene Expression to Predict Long-Term Neurodevelopmental Outcome in Infants from the NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC) Study – A Multicentre Prospective Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- congenital heart disease
- Sponsor
- The University of Queensland
- Enrollment
- 868
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Enrolled in the NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC; ACTRN12617000821392\) randomised controlled trial
- •\* Consent of parents/guardian for long\-term follow\-up
Exclusion Criteria
- •Children are enrolled in the original NITRIC RCT are eligible for this study, therefore the same exclusion criteria as for the NITRIC RCT will apply:
- •Signs of persistently elevated pulmonary vascular resistance preoperatively requiring inhaled NO or preoperative intravenous use of drugs involved in the NO pathway such as glyceryl trinitrate, within 48 hours prior to CPB (oral sildenafil treatment alone is not an exclusion);
- •Patient is on ECLS immediately prior to surgery;
- •Chronic ventilator dependency;
- •Concurrent known confirmed bacterial sepsis/septic shock, diagnosed within \<48hours prior to surgery and being actively treated with antibiotics at time of surgery (suspected sepsis treated with antibiotics is not an exclusion criteria unless inotropes are required for treatment of septic shock at time of surgery);
- •Preoperative acute respiratory distress syndrome requiring high frequency oscillatory ventilation \<48 hours of surgery;
- •Patient requires high doses of vasoactive drugs prior to surgery with an inotrope score \>\=15 met within 24 hours prior to surgery: Inotrope requirement will be calculated by means of the Vasoactive\-Inotrope Score (VIS) (2\): VIS \= dopamine dose (mcg/kg/min) \+ dobutamine dose (mcg/kg/min) \+ 100 x adrenaline dose (mcg/kg/min) \+ 100 x noradrenaline dose (mcg/kg/min) \+ 10 x milrinone dose (mcg/kg/min) \+ 10,000 x vasopressin dose (U/kg/min);
- •Cardiac arrest within one week (seven days) prior to surgery;
- •Emergency cardiac surgery which may preclude obtaining informed consent (defined as acutely required life\-saving procedure in a patient unlikely to survive the next hours without the surgery); and
- •Pre\-existing methaemoglobinemia (MetHb\>3%).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Adolescent neurobiological predictors of developing psychosispsychosisschizophrenia10039628NL-OMON36521niversitair Medisch Centrum Utrecht264
Recruiting
N/A
Research on gene expression regulated by long-term erythromycin therapy for chronic respiratory diseasechronic respiratory diseaseJPRN-UMIN000022281Department of Pathophysiology and Host Defense, The Research Institute of Tuberculosis -Japan Anti-Tuberculosis Association20
Active, Not Recruiting
N/A
Gene expression as predictive markers of outcome in non-small cell lung cancer patients (stage IIIB with pleural effusion and stage IV) treated with chemotherapy. Phase II trial of GOIRC. - NDpatients with non-small cell lung cancer cells in stage IIIB (with supraclavicular lymphnode metastases and / or pleural effusion) or IV, not previously treated with chemotherapy for advanced diseaseMedDRA version: 9.1Level: SOCClassification code 10029104EUCTR2009-017094-38-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
Completed
N/A
GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)GM1 GangliosidosisSandhoff DiseaseTay-Sachs DiseaseNCT05109793Azafaros A.G.31
Completed
N/A
Predicting the prognosis of neurodegenerative diseases by functional MRIAlzheimer's disease MCI (Mild Cognitive Impairment)JPRN-UMIN000009327Kyoto University Hospital30